Reference
·Supporting source
Thailand AI drug discovery operator concentration (2027 estimate)
BIOTEC ~18%, Mahidol ~14%
The 2027 Thai AI drug discovery operator concentration concentrates roughly 75% of addressable revenue across BIOTEC, Mahidol Centre for Computational Drug Discovery, Chulalongkorn Health Innovation Hub, Siriraj Centre of Research Excellence, GPO, Siam Bioscience, Bionet-Asia, and the foreign-partner JVs (Insilico, Atomwise, Exscientia, Iktos Thailand programmes). NSTDA BIOTEC anchors the largest slice at roughly 18% reflecting its USD 35M MTeck-funded Pathum Thani AI Drug Discovery Centre, GPU cluster, and Genome Thailand data-access gateway role. Mahidol's computational chemistry hub sits at 14%, Chula's repurposing-and-pharmacology Hub at 12%, and the mid-tier biotech start-ups plus university spin-outs absorb the residual ~12% long tail.
Figure in context
The 2027 Thai AI drug discovery operator concentration concentrates roughly 75% of addressable revenue across BIOTEC, Mahidol Centre for Computational Drug Discovery, Chulalongkorn Health Innovation Hub, Siriraj Centre of Research Excellence, GPO, Siam Bioscience, Bionet-Asia, and the foreign-partner JVs (Insilico, Atomwise, Exscientia, Iktos Thailand programmes). NSTDA BIOTEC anchors the largest slice at roughly 18% reflecting its USD 35M MTeck-funded Pathum Thani AI Drug Discovery Centre, GPU cluster, and Genome Thailand data-access gateway role. Mahidol's computational chemistry hub sits at 14%, Chula's repurposing-and-pharmacology Hub at 12%, and the mid-tier biotech start-ups plus university spin-outs absorb the residual ~12% long tail.
Interpretation notes
What this tells you
The 2027 Thai AI drug discovery operator concentration concentrates roughly 75% of addressable revenue across BIOTEC, Mahidol Centre for Computational Drug Discovery, Chulalongkorn Health Innovation Hub, Siriraj Centre of Research Excellence, GPO, Siam Bioscience, Bionet-Asia, and the foreign-partner JVs (Insilico, Atomwise, Exscientia, Iktos Thailand programmes). NSTDA BIOTEC anchors the largest slice at roughly 18% reflecting its USD 35M MTeck-funded Pathum Thani AI Drug Discovery Centre, GPU cluster, and Genome Thailand data-access gateway role. Mahidol's computational chemistry hub sits at 14%, Chula's repurposing-and-pharmacology Hub at 12%, and the mid-tier biotech start-ups plus university spin-outs absorb the residual ~12% long tail.
What not to do with it
Share of addressable 2027 Thai AI drug discovery and pharma biotech AI-tooling pool (THB 14-24B mid-case). Excludes downstream local manufacturing economics captured by GPO and Siam Bioscience for AI-discovered compounds.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand AI drug discovery and pharma biotech AI-tooling revenue (2024-2028)
NSTDA BIOTEC, Genome Thailand programme, SCB EIC pharma outlook, PReMA industry profile, foreign-partner disclosures
Thailand AI drug discovery activity mix (2027 estimate)
NSTDA BIOTEC; Siriraj Centre of Research Excellence; SCB EIC pharma outlook; PReMA industry profile
Genome Thailand WGS cohort buildout (2024-2027)
Ministry of Higher Education, Science, Research and Innovation; NSTDA Genome Thailand programme; NSTDA annual report
BOI Section 8 AI compute credit (effective Q1 2026)
Thailand Board of Investment Section 8 R&D announcement
Foreign-pharma Thailand clinical-trial spend (2025-2027)
AstraZeneca Thailand R&D briefings; Roche Thailand personalised healthcare disclosures; SCB EIC pharma outlook
Thailand AI drug discovery cost-per-validated-target (2026)
NSTDA BIOTEC; Mahidol Centre for Computational Drug Discovery; SCB EIC pharma outlook
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.